Henry Schein (NASDAQ:HSIC) Rating Increased to Outperform at Robert W. Baird

Robert W. Baird upgraded shares of Henry Schein (NASDAQ:HSIC) from a neutral rating to an outperform rating in a research report released on Monday, Marketbeat Ratings reports. They currently have $92.00 price objective on the stock, up from their prior price objective of $81.00.

Several other equities research analysts have also recently weighed in on HSIC. Piper Sandler reiterated an overweight rating and issued a $86.00 target price on shares of Henry Schein in a research note on Friday, June 21st. Evercore ISI reduced their price objective on Henry Schein from $75.00 to $72.00 and set an in-line rating for the company in a research report on Tuesday, July 9th. UBS Group lowered their price objective on Henry Schein from $82.00 to $80.00 and set a neutral rating on the stock in a research report on Wednesday, May 8th. Finally, Barrington Research reaffirmed an outperform rating and issued a $92.00 target price on shares of Henry Schein in a research report on Friday, July 5th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Henry Schein has an average rating of Moderate Buy and an average price target of $81.67.

Henry Schein Price Performance

Shares of NASDAQ:HSIC opened at $71.04 on Monday. The company has a market cap of $9.10 billion, a price-to-earnings ratio of 24.00, a PEG ratio of 1.73 and a beta of 0.87. The business has a 50 day moving average price of $68.20 and a 200 day moving average price of $71.90. The company has a quick ratio of 1.02, a current ratio of 1.75 and a debt-to-equity ratio of 0.47. Henry Schein has a twelve month low of $60.01 and a twelve month high of $82.63.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $1.10 earnings per share for the quarter, beating the consensus estimate of $1.01 by $0.09. The company had revenue of $3.17 billion during the quarter, compared to analysts’ expectations of $3.21 billion. Henry Schein had a return on equity of 13.51% and a net margin of 3.12%. Henry Schein’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same period in the prior year, the business earned $1.21 earnings per share. Research analysts predict that Henry Schein will post 5.16 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Tempus Wealth Planning LLC increased its holdings in Henry Schein by 6.0% during the 2nd quarter. Tempus Wealth Planning LLC now owns 4,607 shares of the company’s stock valued at $295,000 after purchasing an additional 260 shares in the last quarter. Fifth Third Bancorp raised its holdings in shares of Henry Schein by 41.8% in the second quarter. Fifth Third Bancorp now owns 2,793 shares of the company’s stock valued at $179,000 after buying an additional 824 shares during the last quarter. Neo Ivy Capital Management acquired a new position in Henry Schein during the 2nd quarter worth about $3,681,000. First Citizens Bank & Trust Co. grew its holdings in Henry Schein by 12.6% during the 2nd quarter. First Citizens Bank & Trust Co. now owns 49,993 shares of the company’s stock worth $3,205,000 after acquiring an additional 5,585 shares during the last quarter. Finally, Raymond James & Associates grew its holdings in Henry Schein by 2.0% during the 2nd quarter. Raymond James & Associates now owns 292,166 shares of the company’s stock worth $18,728,000 after acquiring an additional 5,763 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.